Literature DB >> 2165618

Anxiogenic effects of a benzodiazepine receptor partial inverse agonist, RO 19-4603, in a light/dark choice situation.

C Belzung1, R Misslin, E Vogel.   

Abstract

In a light/dark choice procedure, the imidazothienodiazepinone RO 19-4603, given alone, induced a dose-dependent decrease in the time spent by mice in the lit box as well in the number of transitions between the two boxes. These data confirm the anxiogenic intrinsic properties of inverse agonists of the benzodiazepine receptor. Since RO 19-4603 also reversed the anxiolytic effects of ethanol and exhibited proconvulsant properties, it is suggested that the antagonistic action of this drug against ethanol could be due to an additive rather than an interactive process.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2165618     DOI: 10.1016/0091-3057(90)90260-o

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  4 in total

Review 1.  Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs.

Authors:  J W Mandema; M Danhof
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

2.  Social approach-avoidance behavior of a high-anxiety strain of rats: effects of benzodiazepine receptor ligands.

Authors:  Laurent B Nicolas; Eric P M Prinssen
Journal:  Psychopharmacology (Berl)       Date:  2005-12-03       Impact factor: 4.530

3.  The benzodiazepine inverse agonist RO19-4603 exerts prolonged and selective suppression of ethanol intake in alcohol-preferring (P) rats.

Authors:  H L June; J M Murphy; J J Mellor-Burke; L Lumeng; T K Li
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

4.  Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship.

Authors:  J W Mandema; M T Kuck; M Danhof
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.